Loading…
Erasca, Inc. is projected to rise to $23.19 by 2027, a +24% move from its current price of $18.68. ERAS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $17.97 | $18.69 | $19.44 | +0.06% |
| Aug 2 | $17.69 | $18.70 | $19.76 | +0.11% |
| Aug 3 | $17.48 | $18.71 | $20.02 | +0.17% |
| Aug 4 | $17.31 | $18.72 | $20.24 | +0.22% |
| Aug 5 | $17.16 | $18.73 | $20.44 | +0.28% |
| Aug 6 | $17.03 | $18.74 | $20.63 | +0.33% |
| Aug 7 | $16.91 | $18.75 | $20.80 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.91 | $18.75 | $20.80 | +0.39% |
| Week 2 | $16.26 | $18.82 | $21.79 | +0.77% |
| Week 3 | $15.80 | $18.90 | $22.61 | +1.16% |
| Week 4 | $15.42 | $18.97 | $23.33 | +1.55% |
| Week 5 | $15.11 | $19.04 | $24.00 | +1.94% |
| Week 6 | $14.84 | $19.12 | $24.63 | +2.34% |
| Week 7 | $14.59 | $19.19 | $25.24 | +2.73% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Its product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Erasca has license agreements with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds.
The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015.
Erasca was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc. (ERAS) is a clinical-stage biotechnology company focused on therapies for RAS/MAPK pathway cancers. The current price is $19.02 with a market cap of $6.6B and a rank of 1170.
The forecast implies a path of upside beyond the near term, with 2026 showing an average price of $19.02 (range $3.49 to $28.93) and 0% ROI, followed by bullish momentum in subsequent years. By 2030 the average price is projected at $44.89 with a 136% ROI, rising further to a 2040 average of $107.43 (464.8% ROI) and a 2050 average of $314.58 (1,554% ROI).
A major floor 51.2% below — a decisive break under it would weaken the trend.
The nearest floor, 26.8% below — buyers have tended to step in here.
The nearest ceiling, 13.8% above — a clean break opens room to run.
A major ceiling 36.3% above — clearing it would confirm fresh momentum.
Key ERAS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ERAS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.51 | Buy | $18.52 | Buy |
| MA 10 | $18.88 | Sell | $18.69 | Sell |
| MA 20 | $18.94 | Sell | $18.35 | Buy |
| MA 50 | $15.83 | Buy | $16.75 | Buy |
| MA 100 | $15.35 | Buy | $14.90 | Buy |
| MA 200 | $10.83 | Buy | $11.87 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.64 | Neutral |
| Stoch RSI (14) | 22.86 | Neutral |
| CCI (20) | -33.63 | Neutral |
| Williams %R (14) | -72.88 | Info |
| MACD (12,26,9) | -0.32 | Sell |
| ROC (12) | -4.21 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 27.12 | Neutral |
| TRIX (15) | 0.94 | Buy |
| Awesome (5,34) | 1.07 | Buy |
| Ultimate (7,14,28) | 45.21 | Neutral |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 17.97 | Buy |
| ADX (14) | 21.13 | Buy |
| ATR (14) | 0.62 | Info |
Market sentiment is BULLISH despite a near-term neutral setup.
RSI(14) is 60, with a 50-day moving average of $14.13 and a 200-day moving average of $10.00.
Support is at $11.97 and resistance at $21.26. The 30-day range spans $13.79 to $26.23, and annualized volatility is 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.49 | $18.68 | $26.66 | 0% | Neutral | |
| $17.76 | $23.19 | $32.41 | +24% | Bullish | |
| $19.14 | $26.07 | $38.33 | +40% | Bullish | |
| $23.89 | $33.71 | $51.54 | +80% | Bullish | |
| $31.07 | $45.25 | $71.46 | +142% | Bullish | |
| $36.39 | $54.56 | $88.62 | +192% | Bullish | |
| $36.85 | $56.78 | $94.56 | +204% | Bullish | |
| $37.65 | $59.54 | $101.41 | +219% | Bullish | |
| $40.47 | $65.61 | $114.07 | +251% | Bullish | |
| $47.37 | $78.65 | $139.37 | +321% | Bullish | |
| $64.37 | $119.49 | $229.09 | +540% | Bullish | |
| $147.09 | $326.87 | $701.25 | +16.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.49 | $18.68 | $21.82 | +0.00% |
| August 2026 | $15.81 | $18.73 | $22.83 | +0.27% |
| September 2026 | $16.38 | $19.64 | $24.39 | +4.86% |
| October 2026 | $16.39 | $19.84 | $25.01 | +1.02% |
| November 2026 | $16.12 | $19.67 | $25.09 | -0.87% |
| December 2026 | $16.82 | $20.68 | $26.66 | +5.14% |
Click any year to see its month-by-month ERAS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ERAS could reach as high as $26.66, with a base case around $18.68 and support toward $3.49 — roughly 0% from $18.68. Price action looks broadly range-bound.
Expect ERAS to range from $17.76 to $32.41 through 2027. The $23.19 average target implies a +24% move from current prices. That is up +24% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ERAS price prediction for 2028 points to an average of $26.07 (low $19.14, high $38.33) — a potential gain of +40% on today's $18.68. Momentum favours further upside here.
In 2029, ERAS is projected to trade between $23.89 and $51.54, averaging $33.71 — a potential gain of +80% from today's $18.68. That is up +29% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Erasca, Inc.'s 2030 outlook centres on $45.25, within a $31.07 to $71.46 range. That is up +34% on the projected 2029 average. That marks a +142% change versus current levels. Momentum favours further upside here.
By 2031, ERAS could reach as high as $88.62, with a base case around $54.56 and support toward $36.39 — roughly +192% from $18.68. Buyers look set to stay in control over this stretch.
Expect ERAS to range from $36.85 to $94.56 through 2032. The $56.78 average target implies a +204% move from current prices. That is up +4% on the projected 2031 average. Momentum favours further upside here.
The ERAS price prediction for 2033 points to an average of $59.54 (low $37.65, high $101.41) — a potential gain of +219% on today's $18.68. Buyers look set to stay in control over this stretch.
In 2034, ERAS is projected to trade between $40.47 and $114.07, averaging $65.61 — a potential gain of +251% from today's $18.68. That is up +10% on the projected 2033 average. Momentum favours further upside here.
Erasca, Inc.'s 2035 outlook centres on $78.65, within a $47.37 to $139.37 range. That is up +20% on the projected 2034 average. That marks a +321% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ERAS could reach as high as $229.09, with a base case around $119.49 and support toward $64.37 — roughly +540% from $18.68. Momentum favours further upside here.
Expect ERAS to range from $147.09 to $701.25 through 2050. The $326.87 average target implies a +16.5x move from current prices. That is up +174% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ERAS today (≈ 53.533191 ERAS) could be worth
$17,498.5
+$16,498.5 (+1650%) by 2050 · US Dollar
Based on the average projected ERAS price of $326.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ERASwould be worth at today's price.
$1,000 invested in ERAS on Jul 30, 2025 (≈ 645.16131 ERAS) would be worth
$12,051.61
+$11,051.61 (+1105.2%) today · 12.05× · US Dollar
Based on a ERAS entry price of $1.55 vs. today's $18.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.34 | $965.87 | -3.4% |
| 1 month ago | $18.32 | $1,019.65 | +2.0% |
| 3 months ago | $10.03 | $1,862.41 | +86.2% |
| 6 months ago | $10.51 | $1,777.35 | +77.7% |
| 1 year ago | $1.55 | $12,051.61 | +1105.2% |
| All time (5.0y) ago | $19.28 | $968.88 | -3.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ERAS forecast.
Our base-case forecast reaches $37.00 around 2030.
Implied market cap at $37.00: $12.84B
The multi-year forecast shows a bullish trajectory after a neutral start in 2026 and 2027, with the following averages and ROIs: 2026 avg $19.02 (ROI 0%), 2027 avg $22.57 (ROI 18.7%), 2028 avg $24.58 (ROI 29.2%), 2029 avg $34.13 (ROI 79.5%), 2030 avg $44.89 (ROI 136%), 2031 avg $54.18 (ROI 184.9%), 2032 avg $56.05 (ROI 194.7%), 2033 avg $54.52 (ROI 186.7%), 2034 avg $61.65 (ROI 224.2%), 2035 avg $76.65 (ROI 303%), 2040 avg $107.43 (ROI 464.8%), and 2050 avg $314.58 (ROI 1,554%). The sentiment is BULLISH from 2028 onward, reflecting strong upside potential in the longer term, but these are estimates, not guarantees, and actual outcomes may differ.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $44.89 with a maximum of $75.63 and a minimum of $28.75, and a projected ROI of 136% with bullish sentiment.
The forecast sequence turns bullish from 2028 onward, with the 2030 average $44.89 and a 136% ROI, and by 2050 an average of $314.58 with a 1,554% ROI. These are estimates, not guarantees.
Yes. The 2030 forecast lists a maximum of $75.63, with an average of $44.89 and a 136% ROI.
The current price is $19.02 and the market capitalization is $6.6B. The asset rank is 1170.
The 30-day range is $13.79 to $26.23.
Erasca, Inc. Community Discussion
0Share your Erasca, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.